In Europe, most patients with depression access the health care system through primary health care (PHC) and remain at this level. Hence, detection of depression in PHC is key to efforts aimed at improving depression treatment and outcomes. In Spain, a national study showed that seven of ten patients with depression are identified as such by their primary care practitioner (PCP). Detection was associated with education, symptom severity, impairment, and the reporting of psychological symptoms (
1).
An approach to improving decision making in depression care involves the implementation of clinical guidelines. Although adoption of clinical guidelines is hindered by several barriers (
2), when barriers are effectively addressed and guideline recommendations are adhered to, depression outcomes can be improved among primary care attendees (
3).
The emergence of evidence-based medicine has prompted methods for the development and evaluation of clinical guidelines. Adaptation of existing clinical guidelines provides a valid and efficient acceptable approach to guideline development (
4,
5) that has already been used in mental health practice (
6).
In this column, we report on a project undertaken by a team of PCPs based at the PHC District of Málaga, psychiatrists based at the Málaga Regional University Hospital, and a researcher affiliated with the University of Málaga (the Guideline Developing Group [GDG]). Its goal was to improve depression care for adults served at the PHC District of Málaga, Spain, a region with 20 years of experience in collaborative mental health care.
Guideline Development Process
The clinical guideline for depression in PHC was developed following guidelines from the ADAPTE group, an international and multidisciplinary group endorsed by the Guideline International Network (GIN), which proposed a standard approach for clinical guideline development (
1,
7). Below is a description of the implementation of each of the stages of the ADAPTE method.
Identification of common scenarios of clinical uncertainty.
We implemented two external panels whose members were selected on the basis of their experience in collaborative mental health and primary care approaches, one comprising 66 PCPs, charged with drafting an initial list of 40 clinical scenarios, and another comprising 12 members joined by seven PCPs, three psychiatrists, and two psychologists, who reviewed this draft and selected the 37 most relevant clinical scenarios. [A table providing a profile of the 66-member panel is available in an online supplement to this column.]
The clinical scenarios covered areas related to the definition and epidemiological aspects of depression, assessment, and detection and to general and specific treatment decisions [see the online supplement for a list of the clinical scenarios]. There was a high degree of consensus among PCPs on the selection of clinical scenarios, regardless of the PCPs’ depression expertise. On the suggestion of the GDG, the panel included two additional scenarios: depression during pregnancy and among older people.
Identification of relevant clinical guidelines.
We searched for depression clinical guidelines published in English or Spanish between 2004 and 2011. Sources included National Guidelines Clearinghouse, Canadian Medical Association InfoBASE, National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), GIN, New Zealand Guidelines Group, Institute for Clinical Improvement, National Health Service National Library of Guidelines, Turning Research Into Practice Database, and GuíaSalud, the National Catalog of Guidelines of the Spanish Health Care System.
Evaluation of the suitability and relevance of the identified clinical guidelines to the local context.
We assessed the initial pool of clinical guidelines with AGREE, a 23-item appraisal instrument organized into six quality domains of established validity and reliability (
8).
We considered eight clinical guidelines but selected five (
9–
13) after excluding three because of poor methodology or outdatedness. In accordance with AGREE criteria, we selected the NICE guideline as our main source for recommendations (
11) but also used the SIGN guideline (
14). [Scoring for the clinical guidelines is available in the
online supplement.]
Adaptation of recommendations.
We elicited the opinion of 12 external experts—nine PCPs, two psychiatrists, and one psychologist—through a modified Delphi technique (
15). Experts first individually rated the wording and feasibility of the recommendations, taking into account the Spanish clinical context on a 9-point Likert scale. Next, experts met at two face-to-face meetings, where recommendations with low consensus were discussed and voted on.
Recommendations made by the selected clinical guidelines were adopted without any modification if they were fully applicable to the Spanish PHC practice context; were adapted to better fit the Spanish context or resolve contradictions among guidelines [see the online supplement for examples of adapted recommendations]; or were rejected if unsuitable to the Spanish context. If no recommendation fully addressed any of the clinical scenarios, we conducted additional searches to identify recommendations, but none were adapted or developed on the basis of these new searches.
The resulting version included 121 recommendations, 116 of which were adopted without modifications from NICE and 17 of which included two statements. According to the GRADE classification system (
16), 73 recommendations had strong evidence, and 30 had weak evidence.
None of the guidelines provided guidance on several areas of uncertainty (such as frequency and modalities of presentation of depression in PHC, screening in PHC, grief management, role of self-help groups and new technologies, management of treatment resistance, or intolerance).
External review of the newly developed clinical guideline.
We implemented a panel of 16 individuals from Spain, the United Kingdom, and the United States who belonged to a national research network on mental health, had international experience in depression research, or both. They included PCPs, psychiatrists, and a pharmacist. Their mission was to evaluate the relevance, methodological soundness, and clarity of the recommendations and to identify barriers and facilitators for implementation of the clinical guideline.
The reviewers assessed the clinical guideline as a high-quality guideline and suggested minimal changes to improve clarity. As such, the final version was included in GUIASALUD, a national guidelines catalog with stringent quality criteria (
17).
Guideline implementation.
The implementation process was monitored through five performance targets designed by the GDG to evaluate changes in detection, diagnosis, treatment, follow-up, and referral processes. The clinical guideline was implemented through a multicomponent program that included recruitment of PCPs with a special interest in mental health, responsibility for continuous medical education in their PHC centers, or both, who acted as internal facilitators; a training program that involved discussion of active cases; audit and feedback; dissemination of the guideline to all PHC centers that included the distribution of the clinical guideline (full, summary, and pocket versions) and support materials, such as a self-help guide (
18); establishment of guideline-related performance targets for the health centers as well as an incentive program for PHC centers; enablement of access to mental health consultants; and identification of center-specific barriers to be addressed by guideline implementation “leaders.” Broader dissemination efforts included the endorsement of institutional and scientific societies and publicizing the clinical guideline though various media outlets.
Barriers and facilitators to adoption were identified through qualitative interviews with nine PCPs, five psychiatrists, and a pharmacist. Main barriers pertained to competence in depression care, continuity of care, and time constraints. Main facilitators pertained to quality of the clinical guideline and institutional commitment [see the online supplement for details].
Discussion
We sought to develop a clinical guideline for managing depression in PHC by using a methodologically sound approach that involved the adaptation of existing clinical guideline. The initiative produced a set of resources including evidence-based recommendations, algorithms, decision-aid instruments, resources for patients, and so on, to facilitate detection and improve treatment of depression in PHC. The implementation process, still ongoing in Málaga, aims to overcome barriers that may hinder the sustained adoption of clinical guidelines in usual care settings (
19,
20). Sustainability is key. A program to improve depression care that used evidence-based recommendations previously implemented in Spain affected response and remission rates (
21), but clinical benefits shown in the first year had dissipated by year 3 (
22).
The low adoption rate of evidence-based practices in routine practice settings requires ongoing efforts to facilitate and accelerate adoption. Adaptation of clinical guidelines can assist translating the best knowledge into care improvements (
7). It remains unclear, however, whether diffusion of treatment guidelines has any impact on provider behavior, care processes, and patient outcomes and how implementation should be conducted to maximize benefits. We are currently conducting a clinical trial to evaluate whether implementation of the clinical guideline modifies PCP behavior and the extent to which behavior change affects identification of depression and adequacy of antidepressant drug prescribing.
Acknowledgments
The authors are grateful to all reviewers for their help improving the Clinical Practice Guidelines for the Treatment of Depression in Primary Care: Enric Aragonés, M.D., Ph.D., José María Ayarzagüena, M.D., Ph.D., Juan Ángel Bellón, M.D., Ph.D., Antonio Bordallo, M.D., Ph.D., Maria Carmen Fernández, M.D., Ph.D., Carlos Fernández, Phar., Javier García, M.D., Ph.D., María León, M.D., Ph.D., Carlos Martín, M.D., Marina Maté, M.D., Carmen Montón, M.D., Miquel Roca, M.D., Ph.D., Antonio Serrano, M.D., Ph.D., Caterina Vicens, M.D., Ph.D., Ronald Epstein, M.D., Ph.D., and Michael King, M.D., Ph.D.